Capture Bioscience Technology Published in Nature Biomedical Engineering
Demonstrating a Breakthrough in High-Throughput Immune Profiling
Capture Bioscience, a leader in innovative diagnostic technologies, announced that its core Beads by Time-Of-Flight (B-TOF) platform has been published in Nature Biomedical Engineering. The study, “High-throughput multiplexed serology via the mass-spectrometric analysis of isotopically barcoded beads”, Nat. Biomed. Eng 9, 1117–1128 (2025) was led by Capture Bioscience co-founders in collaboration with Stanford University and other institutions. The peer-reviewed publication provides scientific validation of the scalable immune-profiling technology that underpins Capture Bioscience’s platform.
A Breakthrough in Immune System Monitoring
B-TOF integrates isotopically barcoded microbeads with time-of-flight mass spectrometry, enabling ultra-high-throughput antibody detection. Using this platform, researchers measured IgG and IgM responses to multiple SARS-CoV-2 proteins across hundreds of samples—completing tens of thousands of tests within a single reaction. The method requires only nanoliter-scale sample volumes, delivers precise and reproducible results, and shows strong concordance with clinical assays while revealing variant-specific immune signatures.
Expanding the Frontiers of Diagnostic Scalability
Conventional serological assays measure one antigen per test, limiting throughput and cost-efficiency. The approach detailed in Nature Biomedical Engineering overcomes these constraints by combining isotopic multiplexing with bead-based serology, enabling comprehensive immune profiling at population scale. Capture Bioscience continues to advance the B-TOF platform for applications in vaccine monitoring, epidemiological studies, and decentralized diagnostic testing.
Leadership Perspective
“We’re incredibly proud to see the foundational science behind our B-TOF platform recognized in Nature Biomedical Engineering,” said David McIlwain, PhD, CEO and Co-Founder of Capture Bioscience. “This publication establishes the scientific foundation for our mission—to make immune system monitoring scalable, accessible, and clinically impactful.”
Looking Ahead
Building on this milestone, Capture Bioscience is expanding B-TOF development to include broader pathogen and vaccine panels, additional sample types suitable for point-of-care testing, and collaborative clinical validation studies. These efforts aim to translate this innovation into real-world diagnostic and surveillance solutions.
About Capture Bioscience
Capture Bioscience develops advanced diagnostic technologies to address global public health challenges. Through highly multiplexed bead-based serology, the company enables scalable, high-precision immune profiling—delivering solutions that are accurate, accessible, and adaptable for both individual care and population-level monitoring.
Contact:
David McIlwain, PhD - CEO
mcilwain@capturebioscience.com
+1 (650) 427-0783